Interfacial Peptides as Affinity Modulating Agents of Protein-Protein Interactions

Area of Science:

• Biochemistry
• Pharmacology
• Molecular Biology

Background:

• Disease-related protein-protein interactions (PPIs) are key targets for pharmacological intervention.
• PPI interfaces possess unique features like "hot spots" and low mutation rates, offering opportunities for modulation.
• Existing modulators face challenges in targeted delivery, cell penetration, and stability.

Purpose of the Study:

• To review the current state-of-the-art of interfacial peptides as modulators of disease-related PPIs.
• To highlight recent progress in overcoming challenges associated with peptide-based therapeutics.
• To discuss the therapeutic potential of interfacial peptides in preclinical and clinical settings.

Main Methods:

• Review of scientific literature on interfacial peptide design and application.
• Analysis of specific disease-related PPIs targeted by interfacial peptides.
• Evaluation of preclinical (in vitro and in vivo) and clinical trial data.

Main Results:

• Interfacial peptides demonstrate efficacy in modulating various disease-related PPIs.
• Advances in peptide design have addressed issues of targeted delivery, cell penetration, and proteolytic stability.
• Several peptide-containing therapeutic formulations are progressing through clinical trials.

Conclusions:

• Interfacial peptides represent a promising therapeutic strategy for modulating disease-related PPIs.
• The unique properties of PPI interfaces are being leveraged for novel drug development.
• Continued research and clinical investigation are essential for realizing the full potential of interfacial peptide therapeutics.